Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70‐year old: A phase 1/2 study of the acute leukemia French association
暂无分享,去创建一个
H. Dombret | S. Chevret | C. Gardin | O. Reman | P. Rousselot | C. Berthon | E. Raffoux | C. Pautas | H. Farhat | S. Castaigne | S. Chantepie | L. Kammoun
[1] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Bourhis,et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[4] H. Dombret,et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia , 2009, Cancer.
[5] E. Estey,et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. , 2007, Blood.
[6] R. Bouabdallah,et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.
[7] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[8] D. Gilliland,et al. Drug therapy for acute myeloid leukemia. , 2005, Blood.
[9] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Rohatiner,et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .
[11] I. Bernstein,et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.
[12] I. Bernstein. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate , 2000, Leukemia.
[13] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[14] F. Mitelman. ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .
[15] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .